Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Stock Has Average Target Price of $103.00 According to Analysts

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) has been assigned a consensus rating of “Hold” from the twenty-two brokerages that are presently covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and six have given a buy rating to the company. The average 12 month target price among brokers that have covered the stock in the last year is $103.00.

A number of equities analysts have issued reports on the stock. Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a research report on Wednesday, August 5th. Weiss Ratings upgraded shares of Zimmer Biomet from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, September 14th. Zacks Research raised shares of Zimmer Biomet from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 25th. Truist Financial lifted their price objective on Zimmer Biomet from $92.00 to $106.00 and gave the stock a “hold” rating in a research report on Thursday, August 6th. Finally, Royal Bank Of Canada upped their target price on Zimmer Biomet from $101.00 to $110.00 and gave the company an “outperform” rating in a research note on Thursday, August 6th.

Insider Buying and Selling at Zimmer Biomet

In related news, insider Kevin R. Thornal sold 5,691 shares of Zimmer Biomet stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $92.95, for a total transaction of $528,978.45. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Chad F. Phipps sold 3,000 shares of the business’s stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $98.35, for a total transaction of $295,050.00. Following the completion of the transaction, the insider directly owned 65,231 shares of the company’s stock, valued at $6,415,468.85. The trade was a 4.40% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 1.28% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Zimmer Biomet

Hedge funds have recently modified their holdings of the company. BlackRock Inc. acquired a new position in Zimmer Biomet in the 2nd quarter valued at $1,344,282,000. Primecap Management Co. CA acquired a new stake in shares of Zimmer Biomet during the second quarter worth $328,578,000. Norges Bank acquired a new stake in shares of Zimmer Biomet during the fourth quarter worth $221,234,000. Bank of America Corp DE purchased a new stake in shares of Zimmer Biomet in the second quarter valued at $187,480,000. Finally, Franklin Resources Inc. grew its position in shares of Zimmer Biomet by 43.2% in the fourth quarter. Franklin Resources Inc. now owns 6,685,987 shares of the medical equipment provider’s stock valued at $601,204,000 after purchasing an additional 2,017,857 shares during the period. 88.89% of the stock is owned by institutional investors and hedge funds.

Zimmer Biomet Stock Down 1.4%

Zimmer Biomet stock opened at $89.58 on Tuesday. Zimmer Biomet has a fifty-two week low of $79.12 and a fifty-two week high of $106.88. The firm has a market capitalization of $17.09 billion, a price-to-earnings ratio of 21.79, a price-to-earnings-growth ratio of 1.77 and a beta of 0.47. The stock’s fifty day moving average is $96.23 and its two-hundred day moving average is $91.26. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.94 and a current ratio of 1.69.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.01 by $0.06. The business had revenue of $2.18 billion during the quarter, compared to the consensus estimate of $2.13 billion. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%.The business’s revenue was up 4.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.07 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. Analysts predict that Zimmer Biomet will post 8.54 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date of this dividend is Wednesday, September 30th. Zimmer Biomet’s payout ratio is 23.36%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc (NYSE:ZBH) is a medical technology company that develops, manufactures and markets products designed to treat musculoskeletal conditions. Its portfolio includes orthopedic implants and related systems for hip, knee, shoulder and other joint replacements, as well as products used in sports medicine, extremity care and trauma procedures.

The company also provides robotic- and computer-assisted surgical technologies, digital solutions and other tools intended to support orthopedic procedures and patient care.